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Description of the evidence collection method
The present study included a review of articles published in 
the Medline (PubMed) and other databases, without particular 
time limits. The search strategy was based on structured 
questions according to PICO (i.e., the acrostic formed by the 
initials of “patient”, “intervention”, “control”, and “outcome”). 
The following keywords were used:
•  Question 1: Low back pain AND (analgesics OR paracetamol 
OR acetaminophen OR dipyrone);
•  Question 2: (Chronic back pain OR chronic low back pain 
OR chronic lumbar pain OR back pain OR lumbar pain OR 
low back pain OR lumbago) AND (anti-inflammatory agents, 
non-steroidal OR NSAIDs OR aspirin OR indomethacin OR 
diclofenac OR piroxicam OR tenoxicam OR meloxicam 
OR phenyl butazone OR ibuprofen OR naproxen OR nime-
sulide OR cyclooxygenase 2 Inhibitors OR valdecoxib OR 
celecoxib OR etoricoxib);
•  Question 3: (Opioids OR narcotics OR morphine OR oxy-
morphone OR hydromorphone OR tapentadol or morphine 
derivatives OR oxycodone OR hydrocodone OR fentanyl OR 
tramadol OR codeine OR buprenorphine OR metha done 
OR dextro propoxyphene) AND (low back pain OR back 
pain OR lumbar pain);
•  Question 4: (Chronic back pain OR chronic low back 
pain OR chronic lumbar pain OR back pain OR lumbar pain 
OR low back pain) AND (antidepressant OR duloxetine OR 
venlafaxine OR amitriptyline OR nortriptyline OR clomi-
pramine OR imipramine OR desvenlafaxine OR fluoxetine 
OR sertraline OR citalopram OR mirtazapine OR paroxetine 
OR tricyclic antidepressant OR dual anti depressant);
•  Question 5: Low back pain AND (muscle relaxants OR 
cyclobenzaprine OR diazepam OR benzodiazepines OR 
carisoprodol OR tizanidine OR tetrazepam);
•  Question 6: Low Back Pain AND (hyperthermia, induced OR 
diathermy OR ultrasonic therapy OR shortwave therapy OR 
ultrasound OR infrared rays OR microwaves);
•  Question 7: (Transcutaneous electric nerve stimulation OR 
TENS) AND low back pain;
•  Question 8: (Physical exercise program OR exercise therapy 
OR muscle stretching exercises OR exercise movement 
techniques) AND (low back pain OR chronic low back pain);
•  Question 9: (Acupuncture or electroacupuncture) AND (low 
back pain OR lumbar myofascial pain);
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Currently, rehabilitation methods cannot be determined 
without relating the available interventions for low-back pain 
to economic considerations. For this reason, evidence-based 
guidelines help doctors and policy-makers to identify the most 
cost-effective treatments in order for patients to avoid both 
time and financial losses3 (A).
1. What is the benefit afforded by simple 
analgesics to the control of non-specific chronic 
low-back pain, and how long should these drugs 
be used?
Acetaminophen, at a dose of 1,000 mg four times daily per the 
oral route (PO) over four weeks, is inferior to sodium salicylate 
at a dose of 500 mg twice daily with regard to reducing pain 
and disability in individuals with chronic low-back pain of 
more than 6 months’ duration without associated neurologic 
symptoms4 (A).
A combination of acetaminophen (325 mg) and tramadol 
(37.5 mg), given PO 4 times per day over 91 consecutive days, 
improved chronic low-back pain and reduced the absolute 
risk by 88.4% (95% confidence interval (95% CI), 78-99%), thus 
benefitting 1 of every 9 individuals treated with this regimen 
(number needed to treat (NNT) = 9; 95% CI, 5-101). The adverse 
events reported in the treated group included nausea (13%), 
sleepiness (12.4%), and constipation (11.2%). One of every 
8 patients exhibited adverse events5,6 (number needed to harm 
(NNH) = 8; 95% CI, 5-17) (A).
Evidence has been reported regarding the occurrence of 
severe drug-induced hepatitis as an adverse event at doses 
lower than 4 g5 (A).
Recommendation
Acetaminophen, given at a dose of 500 mg 4-6 times per 
day PO over 4 weeks, is recommended for individuals with 
non-specific chronic low-back pain4 (A).
2. What is the benefit afforded by non-steroidal 
anti-inflammatory drugs to the treatment 
of non-specific chronic low-back pain?
Non-steroidal anti-inflammatory drugs (NSAIDs) are used due 
to their antipyretic, analgesic, and anti-inflammatory effects. 
Those agents inhibit the cyclooxygenase (COX) enzyme, which 
exists in at least 2  isoforms, COX-1 and COX-2, and thus 
NSAIDs are classified according to their ability to inhibit 1 of 
the isoforms. The latest NSAIDs are predominantly selective 
COX-2 inhibitors, while the older ones are less selective4 (A).
Non-selective COX inhibitors
Indomethacin, given at a dose of 25 mg thrice-daily over six 
weeks, was similarly effective to piroxicam at a dose of 20 mg/
day for the treatment of chronic low-back pain; these drugs 
•  Question 10: Human engineering AND low back pain;
•  Question 11: Low back pain AND exercise;
•  Question 12: (Low back pain OR lumbar and chronic pain) 
AND acupuncture and economics.
Those keywords were combined according to the subject 
addressed by the question topics (P.I.C.O.). Following an 
analysis of the located articles, those relevant to the study 
questions were selected and analysed to establish evidence 
with which to support the guidelines described herein.
Degree of recommendation and strength of evidence
A:  Experimental or observational studies with greater consis-
tency.
B:  Experimental or observational studies with lesser consis-
tency.
C:  Case reports (non-controlled studies).
D:  Consensus-based opinions without critical assessments; 
physiological or animal model-based studies.
Objective
To provide information with regard to the treatment of 
non-specific chronic low-back pain.
Introduction
The term lumbago is defined as low-back pain. This disorder 
affects both genders and varies from sudden pain to short 
episodes of intense pain. Low-back pain is classified according 
to the patient’s symptoms and the results of diagnostic tests, 
thus allowing for categories with some specificity relative to 
the prognosis1 (A).
Low-back pain is divided into two major types, specific 
and non-specific2 (A), and is considered specific when it 
can be attributed to a cause. The causes might be intrinsic, 
including congenital, degenerative, inflammatory, infectious, 
tumour-related, or mechanical-postural conditions, or 
extrinsic, including imbalances between functional loads and 
the effort required to perform tasks at work and in everyday 
life. Additionally, low-back pain can be caused by postural 
stress and acute injuries that induce structural deterioration2 
(A). In contrast, when no cause can be identified, low-back pain 
is classified as non-specific or idiopathic2 (A).
The recommendations suggested in the present document 
apply to individuals with non-specific chronic low-back pain. 
Persistent pain of more than 12 weeks duration is classified 
as chronic2 (A).
These recommendations do not apply to individuals with 
histories of 1 or more prolapsed intervertebral discs and 
concomitant neurologic symptoms; spinal surgery; infectious 
spondylopathies; low-back pain due to inflammation, malig-
nant or autoimmune disease; congenital spine deformities, 
except for lordosis and scoliosis; compression fractures 
due to osteoporosis; spinal stenosis; and spondylolysis or 
spondylolisthesis2 (A).
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improved the patients’ mobility and ability to perform tasks, 
in addition to affording pain relief. The adverse events more 
commonly reported in association with piroxicam use include 
gastrointestinal irritation, weariness, diarrhoea, cardiovascular 
risk, constipation, and tongue pain7 (A).
Piroxicam beta-cyclodextrin at a dose of 20 mg was more 
efficacious than the same dose of piroxicam, inducing an 
average variation in the pain visual analogue scale (VAS, 
0-100 mm) score of 3.07 ± 1.56 versus 1.75 ± 1.48 after 28 days 
of treatment8 (A).
Diclofenac, given at 150 mg/day over 4 weeks, effectively 
alleviated pain and improved the physical capacity of 
individuals with chronic low-back pain9 (A).
Naproxen, given at 550 mg twice daily for 14 days, proved 
effective in overall pain reduction and also alleviated nocturnal 
and motion-associated pain in individuals with chronic 
low-back pain. Diflunisal, given at 50 mg twice daily for 
14 days, did not induce significant differences compared to 
a placebo. Naproxen and diflunisal were both similar to the 
placebo with respect to the occurrence of adverse events10 (A).
The use of diflunisal at 500 mg twice daily for four weeks 
was superior to acetaminophen at 1,000 mg four times per 
day at reducing pain and disability in individuals with chronic 
low-back pain11 (A).
Ketorolac tromethamine, given at 60 mg in a single daily 
dose (intramuscular injection), effectively treated low-back 
pain and induced a > 30% reduction in pain intensity in 63% 
of the cases. The main adverse events observed were nausea, 
paraesthesia, sleepiness, dry mouth, and pain at the injection 
site12 (A).
Selective COX-2 inhibitors
Nimesulide at 100 mg twice-daily effectively alleviated pain 
in individuals with low-back pain. Its main side effects are 
nausea, abdominal pain, headache, and vertigo13 (A).
Highly selective COX-2 inhibitors
Etoricoxib, at daily doses of 60 and 90 mg, effectively reduced 
the intensity of pain, with average VAS score variations of 
12.94 ± 15.5 mm and 10.29 ± 13.3 mm, respectively, after four 
weeks of treatment and of 10.5 ± 12.2 mm and 7.5 ± 12.70 mm, 
respectively, after 12 weeks of treatment. Side effects were 
reported in 49% of the individuals in the placebo group, 
64% in the 60  mg/day etoricoxib group, and 59% in the 
90 mg/day etoricoxib group; the most common side effects 
were headache, nausea, diarrhoea, upper airway infection, 
pain aggravation, lower limb swelling, fatigue, dysgeusia, 
urinary tract infection, dizziness, abdominal pain, epigastric 
discomfort, and cough14,15 (A).
The efficacy of etoricoxib 60 mg/day with regard to pain 
relief and functional improvement is comparable to that of 
high-dose diclofenac9 (150 mg/day) (A).
Rofecoxib, at a dose of 25 or 50 mg/day, effectively reduced 
pain intensity, with average pain VAS score variations of 
13.5 and 13.81 mm, respectively, compared to placebo, after 
4 weeks of treatment [95% CI; relative risk (RR) = 39%; NNT = 5; 
p < 0.001]. Side effects were reported by 40.8% of the individuals 
in the placebo group, 48.1% in the 25 mg/day rofecoxib group, 
and 46.3% in the 50 mg/day rofecoxib group; the most common 
side effects were headache (10.1%, 8.2%, and 6.6%), diarrhoea 
(3.5%, 7.3%, and 4.8%), and upper airway infection (4.4%, 3.9%, 
and 5.7%) in the placebo, 25 mg/day rofecoxib, and 50 mg/day 
rofecoxib groups, respectively. Overall, rofecoxib at a dose of 
50 mg/day did not exhibit advantages relative to rofecoxib at 
25 mg/day16 (A).
Approximately two-thirds of rofecoxib-treated individuals 
reported significant pain reduction after two days of treatment, 
and this might have been felt as soon as 2 hours after the first 
dose17 (A).
Rofecoxib was recalled in 2004  due to its probable 
association with an increased risk of myocardial infarction or 
stroke following long-lasting continuous use17 (A).
Valdecoxib, at a dose of 40 mg/day, effectively reduced 
pain intensity, with average pain VAS score variations of 
41.9 mm versus 31.1 in the placebo group after 4 weeks of 
treatment (95% CI; RR = 16%; NNT = 6, p < 0.001). Side effects 
were reported by 25% of the individuals in the placebo 
group and 35% in the 40 mg/day valdecoxib group; the most 
common side effects were headache (6% and 9%), upper 
airway infection (4% and 5%), abdominal pain (< 1% and 4%), 
dyspepsia (< 1% and 3%), dizziness (0% and 3%), and diarrhoea 
(5% and 1%) in the placebo and 40 mg/day valdecoxib groups, 
respectively18 (A).
Valdecoxib was recalled in 2005  due to its probable 
association with an increased risk of thrombotic cardiovascular 
events following continuous use18 (A).
Celecoxib, at a dose of 200 mg, given twice daily for six 
weeks, reduced pain intensity by at least 30% in approximately 
65% of the individuals treated (95% CI; RR = 39%; NNT = 5). The 
most common side effects associated with its use are headache 
(5.8-7.2%), nausea (4.2-5.8%), sleepiness (3-4.5%), dizziness 
(4%), diarrhoea (3.7%), fatigue (2.7%), constipation (2%), itching 
(0.3-1.2%), dry mouth (1%) and vomiting (0-0.8%). Celecoxib, at 
a dose of 200 mg twice daily, was more effective and had fewer 
side effects than tramadol chlorhydrate (weak opiate) at a dose 
of 50 mg four times per day19 (A).
Additionally, the combination of celecoxib (approximately 
3-6 mg/kg/day) and pregabalin (approximately 1 mg/kg/day) 
over 4 weeks effectively treated non-specific chronic low-back 
pain, with an average reduction in pain intensity of 38.2%20 (A).
Combination of non-steroidal anti-inflammatory drugs + 
steroid + muscle relaxant
The use of NSAIDs such as tiaprofenic acid (300 mg, twice 
daily), piroxicam (20 mg, once or twice daily), and meloxicam 
(7.5 mg, once daily) in combination with a steroidal agent 
(betamethasone) and a muscle relaxant (tetrazepam) 
effectively treated individuals with non-specific chronic 
low-back pain, with 5-6-point reductions in the pain VAS 
scores (0-10). The main adverse events associated with the 
use of this combination were epigastric pain and moon face21 
(A).
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Recommendation
Non-selective COX inhibitors can effectively manage pain in 
individuals with chronic low-back pain. The following agents 
are recommended for that purpose: indomethacin at 25 mg, 
thrice daily over six weeks; piroxicam at 20 mg/day; diclofenac 
at 150 mg/day over four weeks; or naproxen at 550 mg, twice 
daily over 14 days. Although non-selective NSAIDs are well 
tolerated, they might be associated with mild-to-severe 
gastrointestinal complications, usually after long periods of 
use7-12 (A).
Selective COX-2 inhibitors such as nimesulide at a twice-
daily dose of 100 mg or meloxicam at 7.5 mg/day in combination 
with a steroid (betamethasone) and a muscle relaxant 
(tetrazepam) effectively alleviated low-back pain13,21 (A).
Highly selective COX-2 inhibitors such as celecoxib, at a 
twice-daily dose of 200 mg over six weeks, and etoricoxib 
at 60  mg/day can effectively manage chronic low-back 
pain8,14,15,19 (A).
Although the highly selective COX-2 inhibitors exhibit 
a lower incidence of adverse gastrointestinal events than 
non-selective COX-2 inhibitors, some studies have indicated 
an increased cardiovascular risk. Thus, it should be noted 
that the length of use is a determinant of this risk, as the 
increase in cardiovascular events occurs after 6 months of 
treatment22 (C).
Increased cardiovascular risk is also associated with 
advanced age, arterial hypertension, previous myocardial 
infarction, previous cardiovascular disease, rheumatoid 
arthritis, chronic kidney disease, and chronic obstructive 
pulmonary disease, among other factors23 (C).
3. What is the benefit afforded by opiates 
and derivatives to individuals with non-specific 
low-back pain, and when should these drugs 
be indicated? How long should they be used?
Opiates versus placebo
Tramadol combined with paracetamol versus placebo
The combined use of tramadol and paracetamol (T/P) induced 
improvements in pain, disability, and the quality-of-life related 
to moderate-to-severe non-specific chronic low-back pain 
(VAS ≥ 40 mm) after 90 days of treatment, with a satisfactory 
safety profile24 (A).
A study using 318 patients (161 T/P, 157 placebo) at an 
initial dose of 1-4 tablets (37.5/325 mg per tablet), increasing 
to a maximum of 8  tablets/day, in four daily doses with 
a 10-day titration period was performed. At the final 
assessment, pain had decreased by ≥ 30% on a VAS (0-100). 
At the end of treatment (90 days), the T/P group exhibited 
better results compared to the placebo group, with a relative 
risk reduction (RRR) = 23% [95% CI, 5-41%), an absolute risk 
reduction (ARR) = 13.7% (95% CI, 2.9-14.5%), and a NNT = 7 
(95% CI, 4-35%]. That effect was also observed relative to an 
outcome improvement ≥ 50% on the pain VAS over the same 
90 days of treatment, with a RRR = 16% (95% CI, 0-32%), an 
ARR = 10.6% (95% CI), and a NNT = 9 (95% CI). T/P also induced 
improvements in the Roland Disability Questionnaire (RDQ) 
scores, with a reduction of 4.1 versus 2.6 (p < 0.023) for the 
placebo, as well as in the quality-of-life scores as assessed by 
the Short-Form McGill Pain Questionnaire (SF-MPQ), with a 
reduction of 8.4 versus 4.8 points for the placebo (p = 0.021). 
The occurrence of adverse effects was higher in the T/P 
group, compared to the placebo group (NNT = 5; 95% CI, 4-8). 
The most common side effects of tramadol included nausea 
(13% versus 3.2% placebo; p = 0.001), sleepiness (12.4% versus 
1.3% placebo; p < 0.001), and constipation (11.2% versus 5.1% 
placebo; p = 0.031), while no severe adverse effects occurred 
during the 90 days of treatment. The average tramadol dose 
was 4.2 tablets/day24 (A).
Tramadol monotherapy versus tramadol and paracetamol
T/P (37.5/325 mg) exhibited the same results as tramadol alone 
(50 mg), but with fewer side effects over 10 days of treatment 
for non-specific sub-acute (10-42 days’ duration) low-back 
pain25 (A).
The initial treatment was 4 daily intakes, with a titration 
period of 3 days, up to a maximum of 8 daily intakes of 
P/T (300/2,600  mg) and P (400  mg). The medication was 
administered over a 10-day period. The patients’ global 
satisfaction rates regarding the treatments after 10 days were 
72.5% (P/T) and 72.9% (tramadol), and the final VAS scores were 
27.9 (P/T) and 24.8 (tramadol), with no significant difference 
between the groups. Although it did not interfere with global 
satisfaction, the number of side effects was significantly 
lower in the P/T group than in the tramadol group (30/59 
(50.8%) versus 44/60 (73.3%); p = 0.019). Two side effects were 
particularly significant: nausea, which occurred in 8 (13.6%) 
cases from the P/T group versus 21 (35.0%) from the tramadol 
group (p < 0.012); and dizziness/vertigo, which occurred in 
3 (5.1%) cases from the P/T group versus 15 (25%) from the 
tramadol group (p < 0.006; 95% CI; RR = 16%; NNT = 5). No severe 
adverse effects were reported25 (A).
Buprenorphine transdermal system monotherapy
In individuals with chronic low-back pain, regardless of the 
cause (nociceptive or neuropathic), the use of a buprenorphine 
transdermal patch effectively controlled pain for a 4-week 
period, with a satisfactory safety profile26 (A).
Buprenorphine transdermal system (BTDS) at doses of 5, 
10, and 20 mg/h, beginning at 5 mg/h with weekly titrations of 
5 mg/h or 10 mg/h until appropriate analgesia is achieved, up to 
a maximum dose of 20 mg/h, reduced pain after 4 weeks of use 
(VAS scores, 37.6 ± 20.7 mm versus 43.6 ± 21.2 mm, p = 0.0487; 
pain ordinal scale26 (0-5: no pain, little pain, moderate pain, 
severe pain, excruciating pain; 1.7 ± 0.6 versus 2.0 ± 0.7, 
p = 0.0358) (A).
However, the functioning and quality-of-life scores 
did not differ between the groups. The following adverse 
effects were more frequent in the BTDS group compared to 
the placebo group: nausea (38.4% versus 16.9%, p < 0.0330) 
and sleepiness: (30.1% versus 6.2%, p < 0.0010), while no 
statistically significant differences were found in the 
occurrence of constipation, vomiting, itching, and dizziness. 
Severe adverse effects did not occur after the use of BTDS for 
four weeks26 (A).
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Hydromorphone extended-release monotherapy
Individuals who used opiates for moderate-to-severe 
non-specific chronic low-back pain achieved satisfactory pain 
control with hydromorphone extended-release compared to a 
placebo27 (A).
Initially, hydromorphone (available in 4, 8, 16, and 32-mg 
doses) titration was performed, beginning with an initial single 
daily dose equivalent to the opiate in use, according to the ratio 
morphine:hydromorphone = 5:1. Titration was performed by 
increasing the amount up to 2 doses per week, to a maximum 
dosage of 64 mg/day (average, 37.2 mg/day). The baseline scores 
of the groups on a pain numerical scale after the initial drug 
titration were 3.1 and 3.2 units. The hydromorphone group 
exhibited less pain reduction (+0.2 score units) compared to the 
placebo group (+1.6; p< 0.001) at the end of the 12-week period. 
Approximately 60.6% of the patients in the hydromorphone 
group achieved at least a 30% reduction in their daily pain 
scale scores (0-10), versus 42.9% in the placebo group (p = 0.01); 
while 42.4% of the individuals in the hydromorphone group 
and 24.1% in the placebo group achieved > 50% reductions in 
their daily pain scale scores (p = 0.01).
Statistically significant changes were also observed 
on a 24-point disability scale, with average variations of 
0.0 versus +1.0 in the hydromorphone and placebo groups, 
respectively (p < 0.005) at the end of the 12-week period. The 
main adverse effects reported were constipation, nausea, 
vomiting, sleepiness, and headache; significant differences 
were observed between the groups with regard to constipation 
(7.5 versus 3.7%), joint pain (6.0% versus 2.2%), and sinusitis 
(4.5% versus 0.7%). One severe adverse effect occurred in the 
placebo group (vomiting with dehydration and kidney failure), 
which was attributed to abstinence syndrome during the 
opiate discontinuance stage27 (A).
Oxymorphone extended release monotherapy versus placebo
Oxymorphone extended release (ER) effectively treated low-
back pain compared to a placebo in usual opiate users28 (A).
In that study, the initial once-daily dose of OPANA ER 
was equivalent to that of the opiate in use (morphine/
oxymorphone = 3/1). The dose was then titrated by 10-mg 
increases every 3-7 days until pain control was achieved 
(VAS ≤ 40 mm) over 3-5 days. That stage lasted for 4 weeks, 
and the average titrated dose was approximately 105 mg/day. 
Following stabilisation of the titration stage and up to the 
final assessment on week 12, the placebo group exhibited an 
increase of 31.6 mm in their VAS (0-100) scores, versus 8.7 in 
the OPANA ER group (p < 0.0001). The most common adverse 
effects were nausea, constipation, headache, and sleepiness; 
however, there were no statistically significant differences 
between the groups during the 12 weeks of treatment. During 
the 4-week titration stage, 49% of the volunteers exhibited 
nausea, 29% constipation, 29% headache, 28% sleepiness, 22% 
vomiting, and 19% itching28 (A).
Oxymorphone extended versus oxycodone controlled release versus 
placebo
The use of oxymorphone or oxycodone in equivalent doses was 
more effective in the control of chronic low-back pain than did 
a placebo and exhibited the same safety profile29 (A).
In a study, 213  individuals with moderate-to-intense 
non-specific low-back pain who used opiates for at least three 
days were allocated to three groups. One group was given 
oxymorphone ER, another, oxycodone controlled release (CR), 
and the third, a placebo. During the titration stage, which 
lasted 7-14 days, the volunteers were given oxycodone or 
hydromorphone every 12 hours, initially at a dose equivalent 
to the opiate in use. Pain control was monitored without 
using morphine sulphate rescue doses > 30 mg/day. In the 
hydromorphone group, titration involved daily 10-mg increases 
per dose to a maximum dose of 110 mg (average, 79.4 mg/day); 
in the oxycodone group, daily 20-mg increases were given to 
a maximum of 220 mg (average, 155 mg/day). The treatments 
were then maintained for 18 days. Oxymorphone ER and 
oxycodone CR were superior to the placebo with regard to 
changes in pain intensity (VAS 0-100), with changes of −18.21 
(95% CI, −25.83 to −10.58; p < 0.0001) in the oxymorphone ER 
group and −18.55 (95% CI, −26.12 to −10.98; p < 0.0001) in the 
oxycodone CR group29 (A).
In the post-titration stage, only 2 adverse effects were 
significantly more frequent in the opiate-treated groups, 
constipation (p < 0.01) and sedation (p < 0.005); however, no 
statistically significant differences were found in the final 
scores among the three groups, and no serious adverse 
effects were reported. Conversely, in the titration stage, the 
occurrence of adverse effects was significantly higher in the 
two opiate-treated groups, compared to the placebo group, 
albeit with no difference between the two groups. Severe 
adverse effects were observed at that stage, including one case 
of reduced respiratory rate, one case of abdominal pain an 
increased creatine phosphokinase (CPK) level, and low-back 
pain aggravation in one volunteer29 (A).
Opiates versus non-steroidal anti-inflammatory drugs
Tramadol monotherapy versus celecoxib monotherapy
Celecoxib (200 mg, twice daily) was superior to tramadol (50 mg, 
four times daily) for the treatment of moderate-to-severe 
non-specific chronic mechanical low-back pain, and also 
induced fewer side effects30 (A).
Two parallel studies were conducted with different samples, 
in which successful responders were considered those who 
achieved improvements ≥ 30% on the Numerical Rating Scale 
of pain (NSR). In the first study, 63.2% of the celecoxib group 
versus 49.9% of the tramadol HCl group achieved a ≥ 30% 
reduction in their NSR scores (0-10) after six weeks (p < 0.001). 
The second study found successful response rates of 64.1% in 
the celecoxib group versus 55.1% in the tramadol HCl group 
after six weeks (p < 0.008). Among the celecoxib group, 31.1% 
and 30.6% of the volunteers in studies 1 and 2 reported at 
least one adverse effect (most commonly, headache, 7.2% and 
5.8%; nausea, 4.2% and 5.8%; and dizziness, 4.0% and 4.0%, 
respectively). Among the tramadol groups, 45.8% and 46.7% 
of the volunteers in studies 1 and 2 exhibited adverse effects, 
respectively (most commonly, nausea, 19.5% and 15.7%; 
dizziness, 14.1% and 12.6%; and sleepiness, 10.9% and 9.5%, 
respectively; p < 0.000130 (A).
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Naproxen versus oxycodone versus oxycodone + morphine 
extended-release
The combined use of extended-release and short-acting 
opiates was more beneficial to the treatment of non-specific 
mechanical low-back pain compared to controlled-release 
opiate alone and naproxen after 16 weeks of treatment31 (B).
The following three groups of volunteers were tested for 
16 weeks: naproxen at 250 mg, four times daily (N); oxycodone 
at 10 mg, four times daily (O); and oxycodone + morphine 
extended-release (O/M), titrated according to the participants’ 
perception of pain to a maximum dose of 200 mg of opiate/
day. The average pain VAS scores at the end of the 16-week 
experimental stage were lower in the O/M group compared to 
those of the O and N groups, with values of 65.5 (N), 59.8 (O), 
and 54.9 (O/M) (p < 0.001). Nevertheless, the groups’ disability 
scores did not differ. Among the side effects, the most frequent 
were dry mouth, sleepiness, headache, constipation, and 
nausea. The side effects were both more frequent (p < 0.001) 
and less intense in the O/M group, compared to the other 
groups31 (B).
Recommendations
In randomised controlled trials, the individuals with non-specific 
chronic low-back pain who benefitted from opiate use were those 
with moderate-to-severe pain, defined as VAS scores ≥ 40 mm, 
despite the use of analgesics and anti-inflammatory agents, 
including opiates24-30 (A)31 (B).
Combined tramadol and paracetamol use (37.5/325 mg), 
given in 4–8 doses per day over 90 days, significantly improved 
pain, disability, and the quality-of-life related to non-specific 
chronic low-back pain25 (A).
Combined with tramadol and paracetamol (37.5/325 mg), 
given in 4-8 doses per day over 90 days, yielded the same 
results as tramadol alone (50  mg), but with fewer side 
effects after 10 days of treatment for non-specific subacute 
(10-42 days) low-back pain25 (A).
In individuals with chronic low-back pain, regardless of the 
cause (nociceptive or neuropathic), buprenorphine transdermal 
patches effectively controlled pain for 4 weeks of use, with a 
satisfactory safety profile26 (A).
Individuals who used opiates for moderate-to-severe 
non-specific chronic low-back pain for less than six months 
achieved satisfactory pain control over a 12-week period 
with hydromorphone extended-release compared to a placebo27 (A).
The use of oxymorphone extended-release for 4 weeks 
was efficacious and safe for the treatment of low-back pain 
compared to a placebo in usual opiate users28 (A).
The use of oxymorphone or oxycodone at equivalent doses 
for 18 days more effectively controlled of non-specific chronic 
low-back pain compared to a placebo, and exhibited the same 
safety profile29 (A).
Celecoxib use (200 mg, twice per day) for 6 weeks was 
superior to tramadol (50 mg, 4 times per day) for the treatment 
of moderate-to-severe non-specific chronic low-back pain and 
induced fewer side effects30 (A).
The combined use of long-release and short-acting 
opiates was more beneficial for the treatment of non-specific 
mechanical low-back pain compared to controlled-release 
opiate and naproxen during a 16-week treatment period31 (B).
4. Is antidepressant use efficacious 
for the treatment of non-specific chronic 
low-back pain?
Duloxetine, a first-line agent32-35 (A) was efficacious at a dose 
of 60 mg/day for up to 12 weeks; this agent reduced the pain 
VAS scores by an average of 2-3 points. Additionally, duloxetine 
increased the frequency of an improvement in pain of ≥ 30% to 
56% of individuals and of an improvement of ≥ 50% in 47% of 
individuals. Duloxetine at a dose of 12.0 mg/day exhibited the 
same beneficial effects for longer than three months32,34 (A).
All recommended doses of duloxetine induced variable and 
individual improvements in functioning and quality-of-life 
for > 3 months. Approximately 64% of the individuals who used 
duloxetine at doses of 20 mg/day, 36-67% at doses of 60 mg/
day, and 73% at doses of 120 mg/day reported adverse events 
(95% CI; RR = 32%; NNT = 7; p < 0.001). Severe side effects that 
occurred with duloxetine use included asthma, myocardial 
infarction, dyspnoea, chest pain, transient ischaemic attack 
(TIA), toxic myopathy, muscle weakness, and vertigo; these 
were reported by 2.6% of the users. When used at a dose of 
60 mg/day, the most common adverse effects were nausea in 
7.3-22% of users; sleeplessness in 7.3-9%; headache in 4.8-10%, 
dry mouth in 9.7-11%, obstipation, in 2.4-9%; sleepiness 
in 7%, diarrhoea in 2.4-11%; fatigue in 9%; and dizziness in 
2.4-10%32-35 (A).
The results observed with escitalopram at a dose of 20 mg/
day are similar to those observed with duloxetine. The side 
effects associated with both drugs appeared in 36% of the 
users, and the most common ones were dry mouth in 10.2% of 
users, sleeplessness in 7.6%, nausea in 5.1%, dizziness in 5.1%, 
headache in 2.5%, lack of appetite, and obstipation. The NNT 
could not be calculated because the pain intensity scale scores 
(a Likert scale ranging from 0-10), which were the primary 
outcome, were described in a general manner, such that only 
the average pain reductions in the duloxetine and escitalopram 
groups were reported35 (6.4 (1.4) and 6.3 (1.5), respectively) (A).
Nortriptyline, at a progressive dose of 25-100 mg/day, was 
efficacious for at least 8 weeks, inducing an average reduction 
in pain of 22%. Its side effects included dry mouth in 82.1% 
of the individuals, sleeplessness in 71.4%, sedation in 60.7%, 
postural hypotension in 60.7%, constipation in 42.9%, sweating 
in 32.1%, and palpitations in 10.7%36 (A).
One study compared maprotiline, a norepinephrine 
reuptake inhibitor, and paroxetine, a serotonin reuptake 
inhibitor, for the improvement of non-specific chronic 
low-back pain. The authors concluded that maprotiline was 
effective at a maximum dose of 150 mg/day, as it reduced pain 
by 45% compared to 27% with placebo (p = 0.023) and 26% with 
paroxetine (30 mg/day over 8 weeks; p = 0.013). Side effects 
were manifested by 90% of the volunteers, the most frequent 
ones being dry mouth in 85%, sedation in 80%, sleeplessness 
in 70%, orthostatic hypotension in 50%, constipation in 50%, 
palpitations in 10%, and sweating in 5%37 (A).
Bupropion at a dose of 300 mg/day was ineffective, as 
were other selective serotonin reuptake inhibitors such as 
paroxetine in doses up to 30 mg/day36-38 (CI = 95%; RR = 32%, 
NNT = 17; p = 0.013) (A).
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The main reason for patients to discontinue treatment was 
the occurrence of side effects; these were proportional to the 
dose used, as were the beneficial effects32-37 (A).
Recommendation
Antidepressants play a relevant role in the management of 
non-specific low-back pain, albeit with variable efficacy. 
Agents with associated adrenergic effects, such as tricyclic and 
dual antidepressants, exhibited better results when compared 
to selective serotonin reuptake inhibitors, most of which 
exhibited insufficient and doubtful results35-37 (A).
Duloxetine at doses of 20 or 60 mg/day over a 12-week 
period is recommended as a first-choice therapy32-35 (A).
Escitalopram at a dose of 20 mg/day for up to 12 weeks is a 
possible alternative because it induced results similar to those 
observed with duloxetine35 (A).
The use of these agents for > 3 months is not recommended, 
as the occurrence of side effects was observed after that period 
in all studies35-37 (A).
5. What are the advantages of a combination of 
analgesics and muscle relaxants?
Muscle relaxants represent an additional option for the 
treatment of non-specific chronic low-back pain and 
comprise antispastic and antispasmodic agents. The use of 
antispasmodic agents presents specific indications for the 
treatment of muscle disorders, and these agents are subdivided 
into benzodiazepines and non-benzodiazepines39 (A).
Several muscle relaxants are available, including cariso-
prodol, cyclobenzaprine, orphenadrine, and tizanidine among 
the non-benzodiazepines and diazepam and tetrazepam 
among the benzodiazepines39 (A). With diazepam, muscle 
relaxation occurs as a rebound effect of central sedation39 
(A).
Muscle relaxants exhibited better results than a placebo 
relative to an improvement in pain by the 8th day of treatment. 
Tizanidine (2 mg/day + diclofenac 50 mg/day over 8 days; 
p < 0.05) and cyclobenzaprine (5 mg/day over 7-10 days, 
p = 0.003) are the most widely investigated muscle relaxants 
for chronic low-back pain40,41 (B).
Tizanidine (2 mg/day + diclofenac 50 mg/days over 8 days; 
p < 0.05) and baclofen (30-80 mg/day over 14 days, p < 0.05) 
induced increased postural hypotension and increased the risk 
of falling in older adults; therefore, these agents must be used 
cautiously40 (B).
Cyclobenzaprine is a weak tricyclic antidepressant used as 
a muscle relaxant39 (A).
Nevertheless, no evidence indicates the superiority of any 
muscle relaxant over another for the treatment of non-specific 
chronic low-back pain. Two studies reported the superiority 
of tetrazepam at a thrice-daily dose of 50 mg for 10-14 days 
over a placebo for non-specific chronic low-back pain, with a 
significant improvement in pain on days 7 and 842 (RR = 2.04, 
95% CI; p < 0.001) (B). However, that drug is no longer used as 
muscle relaxant, due to its sedative effects and the potential 
risk of addiction42 (B).
The adverse events associated with muscle relaxants 
include sedation, sleepiness, dizziness, blurred vision, nausea, 
and vomiting. Carisoprodol exhibited the potential for mental 
and physical addiction, which was associated with its active 
metabolite42 (RR = 2.04, 95% CI; p < 0.001) (B).
Cyclobenzaprine is contraindicated in cases with increased 
intraocular pressure or glaucoma. Caution is required in 
individuals with heart disease because, due to its tricyclic 
structure, this agent might induce severe arrhythmias and 
aggravate congestive heart conditions and the myocardial 
function in patients with infarction42 (B).
A review recommended NSAIDs and antidepressants as the 
first choices for the treatment of non-specific chronic low-back 
pain, due to the lack of adequate data supporting the indication 
of muscle relaxants40 (B).
The American Pain Society and the American College of 
Physicians do not recommend the use of muscle relaxants as 
first-choice agents. Instead, drugs such as acetaminophen and 
NSAIDs are recommended.
Recommendation
Muscle relaxants are not recommended as first-choice 
agents for the treatment of non-specific chronic low-back 
pain due to the lack of sound data in the medical literature 
regarding their beneficial effects on pain compared to their 
side effects.
Non-pharmacological conservative 
treatments
6. What physical means are used?
Ultrasound
Ultrasound (US) is a deep-heat modality that uses high-
frequency acoustic vibrations above the human auditory 
range (above 17,000 Hz). The therapeutic frequencies vary from 
0.8-1 MHz at a 0.15-cm wavelength43 (B).
The influence of US was investigated with regard to pain, 
trunk muscle strength, disability, walking performance, 
resistance, mobility, quality-of-life, and depression in 
patients with non-specific chronic low-back pain. That study 
compared the following groups of volunteers: group 1 (n = 20), 
who were subjected to electrical stimulation for 15 minutes 
with 4 electrodes on L2-L4 at 50 Hz and 50 ms, along with 
45 minutes of supervised exercise; group 2 (n = 19), who 
were subjected to US for 10 minutes at a 1-MHz frequency, 
1 W/cm2 of potency, and 5 cm2 of transducer area in slow 
circular motions on the lumbar paravertebral area, along with 
45 minutes of supervised exercise; and group 3 (n = 20), who 
were subjected to the same exercise programme as the other 
2 groups, with no further intervention. The interventions were 
applied to all 3 groups thrice weekly for 6 weeks. The results 
found a lack of statistically significant differences among 
the groups, as all of them exhibited improvements in pain, 
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functional capacity, and muscle strength, as well as positive 
depression and quality-of-life scores44 (p < 0.05) (B).
However, in that study, the quality-of-life scores from the 
Short Form-36 (SF-36) questionnaire showed improvements at 
the last assessment (after 6 weeks) from 44 (44-88) to 88 (66-99) 
in group 2 compared to group 3, the controls, which showed 
score improvements from 52 (44-88) to 7744 (65-100; p = 0.001) (B).
In another study, group 1  was subjected to aerobic 
exercise and a home exercise programme, and exhibited 
statistically significant improvements in pain severity at a 
1-month follow-up compared to the pre-treatment levels 
(VAS 0-100 mm = 57.05 ± 2.5 before intervention; 34.1 ± 27.6 at 
the 1-month assessment; p = 0.002). Group 2 was subjected 
to surface warming of the lumbar region with hot packs for 
15 minutes; continuous US at a 1-MHz frequency, 1.5-W/cm 
intensity, and a 5-cm transducer area in slow circular motions 
over the paravertebral area for 10 minutes; transcutaneous 
electrical nerve stimulation (TENS; 30-40 Hz via the conventional 
method) for 15 minutes, and conventional physical therapy 
thrice weekly for 6 weeks. That treatment regimen induced 
improvements in pain severity (VAS =  61.2 ±  20.5 before 
intervention versus 28.8 ± 28.1 at the 1-month assessment; 
p = 0.001). Group 3 was subjected to home exercise alone 
and exhibited improvements in pain severity, with VAS 
scores of 56.0 ± 19.9 before intervention and 33.6 ± 24.3 at the 
1-month assessment (p = 0.006). Conclusively, no significant 
differences occurred among the 3 groups relative to pain 
intensity, disability, and the psychological state before and after 
treatment. Nevertheless, the group subjected to US and TENS 
exhibited a 47% greater improvement (p = 0.002) compared to 
the other 2 groups at the 1-month assessment45 (B).
Recommendation
The use of continuous US is recommended at a 1-MHz 
frequency, 1-W/cm2 potency, and 5-cm2 transducer area, 
administered by performing slow circular motions on the 
lumbar paravertebral region for 10 minutes, together with a 
supervised exercise programme that focuses on the abdominal 
and lumbar muscles, is preceded by a 5-minute warm-up, 
and is followed by 5 minutes of stretching, thrice weekly for 
6 weeks as a treatment for non-specific chronic low-back 
pain44,45 (B).
US is contraindicated in cases with the risk of gaseous fluid 
cavitation, such as in the eyeball and pregnant uterus, as well 
as on plastic endoprosthesis components, methacrylate, and 
the heart, in which it might cause turbulence in addition 
to cavitation. US is further contraindicated on epiphyseal 
plates, areas with damaged skin, patients with cognitive and 
intellectual deficit, as well as on tumours due to the risk of 
proliferation. US should be avoided on anaesthetic areas and 
joint facets close to regions where the spinal cord is exposed, 
as in laminectomy45 (B).
Thermal water
A randomised controlled double-blind study was conducted 
by Ágata Kulisch et al. that included 71  individuals with 
non-specific chronic low-back pain from both genders, aged 
25-70 years. The participants were subjected to 20-minute daily 
treatment sessions with medicinal water or tap water, both 
at a temperature of 34 ºC, on 21 occasions, and both groups 
underwent additional adjunctive electrotherapy. The study 
parameters were assessed at the baseline, immediately after 
treatment, and after 15 weeks; pain was assessed according to 
a VAS46 (0-100 mm) (B).
After treatment, there were significant improvements in all 
parameters in the thermal water group. These improvements 
remained evident after 15 weeks. A comparison between the 
intervention and control groups revealed significant differences 
in the VAS scores. At the end of 3 weeks of treatment, the 
patients treated with thermal water exhibited significant 
therapeutic responses, manifested by the VAS scores, when 
compared to the control group (−14.8 (95% CI, −18.9 to −10.7) 
versus. −8.2 (95% CI, −14.1 to −2.4), p < 0.05). Fifteen weeks after 
the end of treatment, the difference in the VAS score relative 
to the baseline was significantly higher in the group treated 
with thermal water (−17.6 (95% CI, −22.9 to −12.4) versus –5.246 
(95% CI, −13.9 to 3.4), p < 0.05) (B).
Recommendation
Immersion in medicinal or tap water at a temperature of 34 ºC 
for 20 minutes/day over a 3-week period is recommended for 
the treatment of non-specific chronic low-back pain.
Shortwave diathermy
A prospective randomised study of 97 individuals from both 
genders, aged 20-80 years old, with complaints of chronic 
low-back pain applied a shortwave diathermy protocol. The 
individuals in the intervention group (group A) underwent 
shortwave diathermy on the lumbar region thrice weekly 
for 15 minutes over a 6-week period and were prescribed 
meloxicam at a dose of 15 mg/day, PO47 (B).
A significant difference was observed between the 
groups by the end of the third week, but in most volunteers, 
improvements could only be detected at the end of week 
6; these manifested as score reductions on the scales used, 
including a VAS (combined total score range, 0-34). The 
pre-treatment combined scores were 20.44 ± 3.02 for group 
A and 20.10 ± 3.51 for group B. At the end of week 6, the scores 
were 6.44 ± 3.06 for group A and 13.38 ± 3.10 for group B47 
(p = 0) (B).
Recommendation
Shortwave diathermy is recommended on the lumbar region 
thrice-weekly for 15 minutes per session over a 6-week period 
for the treatment of non-specific chronic low-back pain47 (B).
7. What is the role of electrical stimulation 
in non-specific chronic low-back pain?
The main electrical stimulation modalities used to induce 
analgesia are TENS and percutaneous electrical nerve 
stimulation48 (PENS) (A).
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TENS can be applied at high frequencies (> 50 HZ) and with 
sub-threshold intensities to induce muscle contraction, which 
is known as sensory stimulation, or at low frequencies (< 10 Hz) 
and intensities fit to induce muscle contraction48 (A).
PENS comprises a combination of acupuncture and electrical 
stimulation48 (A). It is believed that PENS should be considered 
an analgesic modality that facilitates the exercise performance 
by individuals with non-specific chronic low-back pain49 (A).
PENS is contraindicated in pacemaker users, except when 
authorised by a cardiologist, as well as in individuals with 
epilepsy, heart problems, or cognitive impairments. Its use 
should be avoided during the first 3 months of pregnancy, 
especially on the lumbar and abdominal areas. Individuals 
with stroke sequelae should not undergo PENS on the face 
and neck49 (A).
A literature review of original articles published in 
English that reported prospective randomised, controlled, 
double-blinded studies observed a substantial superiority 
of analgesic interventions, based on the use of electrical 
stimulation over placebo or multimodal exercise programmes50 
(A).
One prospective study randomly allocated 41 individuals 
with chronic low-back pain to 2 groups, group 1 (n = 21), 
which was subjected to a programme that included TENS and 
exercise, and group 2 (n = 20), which was subjected to exercise 
only and considered the control. Both outpatient programmes 
involved 3 sessions per week over an 8-week period50 (A).
Electrical stimulation was applied for 15 minutes with the 
patient in a prone position and for 15 minutes in a supine 
position. In the prone position, the electrodes were placed from 
L2 to L4 along the motor points for the paraspinal muscles and 
in the supine position, on the motor points for the abdominal 
external oblique muscles. A biphasic symmetrical wave was 
applied at a frequency of 50 Hz and a phase speed of 50 ms. The 
current intensity was adjusted for each individual volunteer 
until apparent muscle contraction was achieved (70-120 mA). 
The stimulus was applied to induce 10 seconds of contraction 
and 10 seconds of relaxation50 (A).
All pain parameters exhibited significant improvements 
in both groups after treatment, albeit these were greater in 
the intervention group (p < 0.001). The Oswestry Disability 
Questionnaire (ODQ) scores measured in the group 1 were 
36.66 ± 9.53 at baseline and 6.57 ± 5.53 at the end of treatment. 
The corresponding scores in group 2 were 37.22 ± 17.04 and 
19.22 ± 13.99 (p = 0.001). For the Pain Disability Index (PDI), the 
group 1 scores decreased from 19 (10-45) to 4 (0-23), while those 
of group 2 decreased from 22 (12-64) to 9.550 (0-48) (p < 0.001) 
(A).
Another randomised clinical trial selected 200 individuals 
from both genders who were older than 65 years old and 
had chronic low-back pain to assess the efficacy of PENS, 
with or without general conditioning and aerobic exercise 
(GCAE), for reducing pain and improving physical functioning. 
The participants were randomised to receive either PENS, 
control-PENS (brief electrical stimulation to control for 
treatment expectancy), PENS + GCAE, control-PENS + GCAE 
twice weekly for 6 weeks. The needles in the intervention 
groups were placed bilaterally at levels corresponding to T12, 
L3, L5, and S2, as well as the motor point of the piriformis 
muscle. Electrical stimulation was applied for 30 minutes 
only at the T12-level. The GCAE programme was performed 
onsite for 60 minutes and included both general conditioning 
(strength and flexibility) and aerobic components. The 
home exercise programme comprised flexibility exercises 
and graded walking as the aerobic component. All 4 groups 
exhibited significant reductions in pain (range –2.3 to –4.1 on 
the McGill Pain Questionnaire short form) that were sustained 
at 6 months. The GCAE groups experienced significantly fewer 
fear-avoidance beliefs immediately post-intervention and at 
6 months than did the non-GCAE groups51 (A).
A comparison of the various analgesic modalities showed 
that PENS was superior to TENS, while the latter was 
comparable to other therapies such as deep diathermy via 
US51 (A).
Transcutaneous electric nerve stimulation versus ultrasound
One study compared the effects of electrical stimulation (ES) 
and US on pain, trunk muscle strength, disability, walking 
performance, spinal mobility, quality-of-life, and depression 
in individuals with non-specific chronic low-back pain. A total 
of 59 volunteers were randomly allocated to 3 groups: group 
1 (n = 20), which underwent a programme comprising ES and 
exercise; group 2 (n = 19), which underwent US and exercise 
treatment; and group 3 (n= 20), which acted as the control and 
performed some conventional exercises. All the programmes 
were conducted thrice weekly for 6  weeks. The results 
indicated improvements in quality-of-life and pain, as assessed 
by SF-36 and by comparing the results at the beginning and end 
of the intervention. An intergroup comparison found similar 
improvements (p < 0.001) in the groups that received ES and 
US44 (SF-36 scores increased from 49 (11-77) to 88 (55-100) and 
from 44 (44-88) to 88 (66-99), respectively) (B).
Another study randomised 60 individuals to 3 groups. Group 
1 performed an aerobic programme and home exercise, group 
2 was subjected to physical therapy (hot packs, US, and TENS) 
and home exercise, and group 3 performed home exercise 
only. All 3 approaches reduced pain and increased the aerobic 
capacity; however, the combination of physical therapy and 
home exercise proved more effective when psychological 
features were considered52 (A).
Transcutaneous electric nerve stimulation versus massage
The first appropriately randomised clinical trials compared 
TENS and massage via negative pressure. A gentle massage 
was produced by placing 4 suction cups on the skin; these 
were kept in place by mild negative pressure within each cup. 
A specially constructed apparatus produced slowly varying 
changes in pressure so that a constant, gentle massage was 
applied to the skin. Electrical stimulation was applied by an 
active electrode that was placed securely at the centre of the 
painful area of the back, and a second electrode was placed 
on the lateral aspect of a thigh. The output frequency was 
set at 4-8 Hz, and the current intensity was raised until the 
patient reported that it was unpleasant. The intensity was 
 REV ASSOC MED BRAS. 2013;59(6):536-553 545
then reduced to a level that the patient reported tolerable. 
Adjustments to the intensity were made during the session 
to maintain the same tolerable level. The intervention 
was applied twice weekly for 30 minutes per session until 
improvement or the completion of 20 sessions. All patients 
received the same standard exercises for low-back pain at 
the conclusion of each stimulation session. The results 
showed improvements in pain > 50% in 85% of the volunteers 
subjected to TENS versus 38% of the participants subjected to 
massage53 (A).
Transcutaneous electric nerve stimulation versus percutaneous 
electrical nerve stimulation
One study sought to establish the number of PENS sessions 
needed to alleviate chronic low-back pain and for how 
long analgesia is sustained. Individuals with peak pain 
intensities < 40 on a VAS (0-100) were subjected to twice-weekly 
interventions for eight weeks. Group A (n = 18) received PENS 
for eight weeks, group B (n = 17) received PENS for the first four 
weeks and TENS for the second four weeks, and group C (n = 18) 
received TENS for eight weeks. The pain level, degree of physical 
impairment, and daily NSAID intake were assessed before and 
3 days after the first treatment, during weeks 2, 4, and 8 of 
treatment, and at 1 and 2 months after the sessions54 (A).
During PENS, the pain level decreased significantly after 
week 2 in group A (VAS score: from 55 ± 11 to 37 ± 10) and 
group B (from 56 ± 9 to 36 ± 13) (p 0.05 or 0.01), and physical 
impairments and required NSAID intake decreased significantly 
after week 4 in group A (p 0.05 or 0.01), but only at week 8 (p 
0.05 or 0.01) in group B. These effects were sustained until the 
1-month follow-up (p < 0.01) in group A, but not in group B, 
while they were not observed at the 2-month follow-up even 
in group A. In group C, the pain level decreased significantly 
only at week 854 (p < 0.05) (A).
Recommendation
Electrical stimulation and the other physical means are 
thought to facilitate analgesia in the affected individuals 
in order to achieve physical rehabilitation through exercise 
programmes designed for non-specific chronic low-back 
pain; these programmes not only induce gains in but also 
maintain the range of motion by stimulating flexibility and 
strengthening the muscles that stabilise the trunk and the 
abdomen, in addition to the gluteal muscles.
Both TENS and PENS are recommended, albeit with some 
restrictions derived from their contraindications and side 
effects.
TENS involves the application of a biphasic symmetrical 
wave at a 50-Hz frequency and a 50-ms phase. The current 
intensity must be established on an individual basis until 
apparent muscle contraction is achieved (60-130  mA). 
Stimulation must be applied to induce contraction for 
10 seconds and relaxation for 10 seconds55-57 (B). Bilateral 
placement of the electrodes at the level of L2 to L4 on the spinal 
erectors motor points51 is recommended (A).
The advantages of TENS include the possibility of home 
application without the need of a trained professional to place 
the electrodes, as the patient can be sufficiently trained and 
can understand the instructions given to ensure appropriate 
use, provided contraindications do not apply.
For PENS, it is recommended to bilaterally place the needles 
at the levels corresponding to T12, L3, L5, S2, and at the 
piriformis muscle motor point; stimulation must be applied for 
30 minutes at T12 and for 15 minutes at the other sites twice 
weekly for eight weeks. Additionally, a 60-minute exercise 
programme should be indicated with the intent to promote 
strength and flexibility, along with an aerobic component.
It is worth observing that the use of TENS and PENS without 
a specific exercise programme does not suffice to maintain 
analgesia over a long period of time because those therapies 
merely facilitate the performance of specific rehabilitation 
exercises51 (A)58 (B).
8. What is the benefit of exercise in the treatment 
of non-specific chronic low-back pain?
Several models have been put forth for the treatment of 
non-specific chronic low-back pain, but none have proved 
more efficacious than the others59-63 (B).
Exercise programmes are used to provide relief to individuals 
with non-specific chronic low-back pain. Such programmes 
usually involve an aerobic component, strengthening and 
stretching, and orientation59-63 (B).
A general exercise program that included stretching, 
strengthening, and a warm-up induced pain reduction, and 
the positive effects were preserved for 5 years59 (p = 0.01) (B).
Programmes such as the back school induced improvements 
in pain intensity, functional capacity, and lumbar spine 
mobility compared to the controls60(B).
Nevertheless, comparisons of various approaches such 
as intensive training, back school, and combinations of 
behavioural and physical therapy did not find significant 
differences61 (B).
A motor control exercise programme induced significant 
improvements when compared to general exercise and spinal 
manipulation/mobilisation after 8 weeks of treatment62 (B).
A study assessed rehabilitation programmes, including 
resistance training, and found that these exercise modalities 
improved musculoskeletal health, pain, and disability after 
8 weeks and were safe and effective for the rehabilitation of 
individuals with non-specific chronic low-back pain63 (B).
One study of a 10-station exercise class that involved 
aerobic exercises, spinal stabilisation exercises, and manual 
therapy (spinal mobilisations) for 30 minutes per session 
over an 8-week period observed improvements in pain at 
6 and 12-month assessments. According to some studies, 
such modalities are more beneficial when performed as 
1-to-1 treatments than in a group. The parameters assessed in 
the abovementioned study included lumbar flexion, whereby 
while standing, the volunteers were asked to slide their 
hands down the front of their legs until they experienced the 
ﬁrst point of pain or the ﬁrst increase in pain. The distance 
from the end of the middle ﬁnger to the ﬂoor was measured 
with a standard tape measure, and the volunteers were then 
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requested to mark the intensity of pain on a pain VAS, where 
the left side represented no pain and the right side represented 
the worst pain imaginable. Additionally, the study measured 
lumbar extension, which was measured similarly with the 
volunteers sliding their hands down the posterior aspect of 
their legs; left and right-side flexion, which were measured in 
the same manner with the volunteers sliding their hands down 
the lateral aspects of their left and right legs, respectively; 
and the straight leg raise (SLR), while in a supine position, 
the ranges of left and right SLR were measured by placing an 
inclinometer (Isomed, Portland, OR) on the tibial tuberosity; the 
leg was passively elevated, and the angle at the ﬁrst point of 
pain or ﬁrst increase in pain was read from the inclinometer; 
the volunteers then marked the intensity of pain on the VAS 
(pain) line.
At 12 months after treatment, there were mean increases of 
8.5 cm in the ﬂexion range, 2 cm in the extension range, 2.5 cm in 
the left-side ﬂexion range, 2.7 cm in the right-side ﬂexion range, 
12.6° in the left SLR range, and 10.5° in the right SLR range in 
the exercise group. The corresponding results for the individual 
treatment group were 12.5 cm (ﬂexion), 1.5 cm (extension), 2.5 cm 
(left-side ﬂexion), 1.3 cm (right-side ﬂexion), 12.1º (left SLR), and 
12.2º (right SLR); except for the left and right side flexion values, 
all results were superior in the individual group.
At 12 months, statistically signiﬁcant decreases in the VAS 
(pain) scores were observed for all movements except left side 
ﬂexion in the exercise group. At 12 months, 21 of 33 subjects 
(63.6%) who had participated in the exercise group felt that they 
had improved, and 12 of 33 (36.4%) felt that they remained the 
same as at the beginning of the study. The mean percentage 
improvement at 12 months was 62.9% (range, 20-100%). The 
corresponding data for the individual treatment group at 
12 months were that 75.8% of the volunteers improved (range, 
12-95%), while 7 of 29 (24.1%) remained the same.64 (B).
Recommendation
Exercise is indicated for the treatment of non-specific chronic 
low-back pain. However, several types of exercise have 
been reported in the literature, while most studies in fact 
applied combinations of several types to a single intervention 
group. As a result, there is no sound evidence to indicate the 
superiority of any 1 type of specific exercise over any other 
for the treatment of non-specific chronic low-back pain. That 
fact notwithstanding, all studies found improvements in pain, 
independent of the exercise type and frequency59-64 (B).
9. What is the benefit of acupuncture in the 
treatment of non-specific chronic low-back pain?
Acupuncture + conventional treatment versus conventional 
treatment alone
Combinations of acupuncture and conservative therapies 
such as physical therapy, NSAIDs, analgesia, heat, self-care, 
and postural education are more beneficial than conservative 
treatments alone65-67 (B).
One 12-week study of 55 individuals with chronic low-back 
pain found a greater benefit relative to symptoms and function 
in the group treated with a combination of electroacupuncture 
and usual care, which included analgesics, NSAIDs, and 
physical therapy without TENS, compared to the group that 
continued their usual care only65 (B). Electroacupuncture 
was performed at 4-6 Hz with a pulse duration of 0.5 ms 
twice weekly for five weeks, for a total of 10 sessions. DeQi 
responses were achieved at all points, and 10-14 needles 
were used per session on acupoints BL23, BL24, BL25, BL28, 
Du3, and Du4, with up to 4 additional needles in cases with 
radiating leg pain on the following acupoints: BL 36, 54, 37, 
40, GB 30, and 31. Each session lasted for 20 minutes. The 
group treated with acupuncture and usual care exhibited 
the following results compared to the group that continued 
their usual care only (control group): a decrease in the Roland 
Disability Questionnaire (RDQ; 0-18) score of 4.1 ± 3.9 at 
week 6 versus 0.7 ± 2.8 (control group; p = 0.001). This effect 
was maintained for up to 4 weeks after treatment (week 9), 
with a decrease in the RDQ score of 3.5 ± 4.4 from baseline 
compared to 0.43 ± 2.7 for the control group (p < 0.007). There 
was no significant change relative to the pain VAS (0-10) in 
the acupuncture group at week 6; however, by week 9, the 
individuals treated with acupuncture showed decreased pain 
scores (−0.2 ± 1.3) compared to the control group, which had 
a pain score increase of 0.7 ± 1.1; this difference between the 
groups was statistically significant65 (p < 0.02) (B).
The greatest benefit induced by the use of acupuncture 
combined with conservative orthopaedic treatments (COT) 
such as physical therapy, exercise, infrared heat therapy, back 
school, and mud packs compared to COT alone manifested 
6 months after the onset of treatment, or 3 months after the 
last session66 (A).
One study performed 12 sessions of acupuncture, thrice 
weekly, and the needles were placed on the following points: 
BL 23, 25, GB 30, BL 40, 60, and GB 34; additionally, up to 
4 “AhShi points” in the lumbar area were needled. Needle 
manipulation was mild to strong. DeQi was achieved for 
30 minutes. Treatment with acupuncture + COT achieved 
a success rate (> 50% score reduction on a pain VAS from 
0-100) of 67% (95% CI, 62-88%) at six months after the onset 
of treatment (three months after the last session) versus 14% 
(95% CI, 4-30%, p < 0.001) of those treated with COT alone66 (A).
One study compared traditional body and ear-acupuncture 
combined with physical therapy to physical therapy alone in 
individuals with non-specific mechanical low-back pain for at 
least 6 months. All volunteers received 26 sessions (30 minutes 
each) of standardised active physical therapy (PT) for 12 weeks, 
and the acupuncture group (AG) additionally received 
20 sessions of combined traditional body and ear-acupuncture 
five times per week during the first two weeks of treatment 
and once per week for the next ten weeks. Acupuncture was 
found to be superior to the control treatment (CG) with regard 
to pain intensity and disability at the end of treatment, and 
this benefit was maintained at the 9-month follow-up67 (B).
The DeQi sensation was elicited and the needles 
(0.3 × 40 mm) were left in place for 10-30 minutes. Twenty 
needles were used in body-acupuncture, at nine bilateral 
and two single points: BL23, BL25, BL31, BL32, BL40, BL60, 
GB34, SP6, GV3, and GV4, as well as six unilateral ear-points 
(os sacrum (38), parasympathicus (51), nervus ischiadicus 
 REV ASSOC MED BRAS. 2013;59(6):536-553 547
(52), lumbosacrum (54), shenmen (55), and kidney (95)). The 
combination of acupuncture and PT (AG) was superior to PT 
alone (CG) after 12 weeks. On the last day of treatment, the 
change in the pain VAS (1-10) scores of the AG versus the CG 
group was −1.7 (95% CI −2.71 to −0.62; p < 0.000), and the change 
in the disability score (PDI, 0-70) was −11.3 (95% CI −17.01 to 
−5.44, p < 0.000). However, only the improvement in disability 
was maintained at the 9-month follow up, whereby the 
difference in within-group PDI score changes of the AG versus 
the CG group was −6.867 (95% CI, −12.57 to −0.96; p < 0.016) (B).
True versus sham acupuncture
There is controversy regarding the efficacy of true acupuncture 
(deep insertion of needles into acupoints) compared to sham 
acupuncture (a more superficial insertion of needles in sites 
distant from acupoints). Some studies found benefits of true 
versus sham acupuncture66,68 (A), while others found both 
techniques to be equivalent67,69 (B).
Nevertheless, it has been proven that acupuncture with 
sham insertion surface is not an inert procedure.
A study conducted by Brinkhaus et al. in 2006  with 
298 volunteers found no benefit of deep acupuncture when 
compared to superficial (subcutaneous) acupuncture when 
needles were placed into the acupoints routinely used 
for chronic low-back pain at weeks 8, 26, and 5269 (A). The 
volunteers were subjected to 12 sessions lasting 30 minutes 
each for 8 weeks, in which the needles (8) were bilaterally 
placed into at least 4 of the following points: BL 20 to 34, BL 
50 to 54, GB 30, and GV 3 to 5, and at least 2 distant points 
among the following: SI3, BL40, BL60, B62, KI3, KI7, GB31, GB34, 
GV14, and GV20. In the group that received subcutaneous 
acupuncture, 6-10 predefined non-acupuncture points were 
used. The lack of significance between the results of both 
groups was maintained at weeks 26 and 5069 (A).
Another study found a benefit with the use of intramuscular 
versus subcutaneous acupuncture for the treatment of 
low-back pain68 (A). The selected points were Extra 19, 
VG6, GB34, BL54, BL62, and an additional fourAhShi points, 
including needle stimulation, which comprised rotation in 
both directions at 2 Hz for 20 seconds during the first minute, 
and then every 5 minutes until the end of the sessions; the 
sessions lasted for 20 minutes and were performed eight times 
during one month. At the end of the treatment, pain reduction 
was greater in the group with deep acupuncture, although 
this difference was not significant. However, at the 3-month 
follow-up, a statistically significant difference existed between 
the groups, with better results in the group subjected to deep 
acupuncture, as determined by McGill Pain Questionnaire 
scores of 7.5 (± 12.94) versus 1868 (± 17.16) (A).
One study of 186 volunteers found a benefit with the 
combined use of true acupuncture and conservative 
orthopaedic treatments (COT) such as physical therapy, 
exercise, infrared heat therapy, back school, and mud packs, 
compared with combined superficial acupuncture and COT, 
at a 3-month follow-up66 (A). The acupuncture involved 
12 30-minute sessions, distributed thrice weekly, and the 
following points were needled: BL23, BL25, GB30, BL40, BL60, 
GB34, and up to four additional AhShi points in the lumbar 
region. The needle manipulation was mild to strong, and 
DeQi was achieved in all cases. The results were as follows: 
the success rate (> 50% reduction of scores on a pain VAS 
scale of 0-100 at three months after the end of treatment) was 
77% (95% CI, 62-88%) in the group subjected to acupuncture, 
and 29% (95% CI, 16-46%) in the sham-acupuncture group; 
this difference was significant (p <  0.001). Immediately 
after the end of the treatment, the success rates were 65% 
in the acupuncture group (95% CI, 51-77%) and 34% in the 
sham-acupuncture group (95% CI, 22-49%). The difference 
between true and sham acupuncture at the 3-month follow-up 
was significant66 (p < 0.02) (A).
No difference in benefit was found between true and sham 
(superficial) acupuncture for the treatment of chronic low-back 
pain at 9 months after treatment67 (B).
True acupuncture versus placebo procedure versus 
transcutaneous electrical nerve stimulation
When considering the quality difference between the two 
studies mentioned in this document it can be said that 
acupuncture has greater efficacy versus TENS and placebo; in 
other words, the quality was higher in one of them70 (A) and 
in the other study, this was not stated71 (B)
One study that compared manual acupuncture or 
electroacupuncture to active placebo (TENS) for the treatment 
of non-specific mechanical low-back pain observed benefits 
with the investigated treatments. A total of 50 volunteers 
were allocated to three groups; two groups included the use 
of acupuncture, and one included inert TENS once weekly for 
eight weeks. In the acupuncture group, 14 points were used 
per session, including BL24, BL25, BL26, BL40, BL57, BL60, LI4, 
LI11, and Ex Jiaji. Each session lasted for 20 minutes, and the 
needles were manipulated until DeQi was achieved three times 
in the session. The same technique and points were used in 
the electroacupuncture group, which further included the 
application of a 2–15-Hz current at 2.5-second cycles on four 
needles, specifically one pair per side, again for 20 minutes. 
One, three, and six months after the end of treatment, 
greater benefits were observed in both groups treated with 
acupuncture compared to the placebo group (TENS), with 
VAS (0-100) score improvements of 13%, 23.5%, and 38.5%, 
respectively, in the acupuncture groups, compared to score 
declines of 28%, 24%, and 16%, respectively, in the placebo 
(TENS) group70 (p < 0.000, p < 0.001, and p < 0.001, respectively) 
(A).
Another study of 46 patients found no significant difference 
between the acupuncture and placebo groups (TENS), although 
this study was of poor quality.72 Both groups were treated 
weekly for 6 weeks, with each session lasting for 30 minutes. In 
the acupuncture group, 11 needles (0.3 × 50 mm) were placed at 
the following points: BL23, BL25, GB30, BL40, KI3, and GV4, and 
DeQi was achieved; the needles were manipulated 3 times per 
session at 10-minute intervals to maintain the DeQi sensation. 
In the TENS group, electrodes were placed on the lumbar 
region. No significant difference was observed between the 
groups at the 4-week and 6-month follow-up71 (B).
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Simulated acupuncture versus true acupuncture
No benefit was found for true acupuncture when it was 
compared to simulated acupuncture, which did not involve 
the actual insertion of needles but instead a mere stimulation 
of the skin, in patients with chronic low-back pain72 (A). The 
following procedures were applied: individualised acupuncture 
(patient in a prone position with no constraints relative to 
the points used, insertion depth, or needle manipulation); 
standardised acupuncture (points Du3, B23, the low-back 
AhShi point, B40, and KI3 for 20 minutes with stimulation 
by twirling the needles at 10 and 20 minutes); and simulated 
acupuncture (no actual needle insertion). The sessions were 
performed twice weekly for six weeks and then weekly for 
four weeks (10 sessions in total). No statistically significant 
difference was found among the three acupuncture groups; 
however, a significant difference was found between these 
groups and a fourth group that received usual care only72 (A).
Acupuncture versus massage
After 10 weekly sessions, acupuncture was inferior to massage 
with respect to pain and disability in patients with non-specific 
chronic low-back pain. That effect was maintained from the 
end of treatment up to a 1-year follow-up73 (B). One study of 
262 volunteers compared the following procedures performed 
in 10 weekly sessions: massage, performed by 12 therapists 
who freely applied commonly used therapies such as Swedish 
(71%); movement re-education (70%); moist heat or cold (51%); 
deep-tissue (65%), neuromuscular (45%), and trigger or pressure 
point (48%) techniques; and acupuncture, the technique of 
which was also freely selected by the acupuncturists and 
included basic traditional Chinese medicine (TCM) techniques, 
needle manipulation, and moxibustion. Massage proved 
to be superior to acupuncture at the end of the treatment, 
according to the modified Roland Disability Scale (RDS, 0-23) 
scores (6.3 versus 7.9, p < 0.01). At a 1-year follow-up, massage 
remained superior to acupuncture with respect to both the 
disability scores (6.29 versus 8.21; p < 0.05) and the symptoms 
scale73 (VAS, 0-100; 3.08 versus 4.74; p < 0.002) (B).
Acupuncture versus anaesthetic injection
Acupuncture proved to be more beneficial than local 
anaesthetic injections at the most painful palpation points 
in patients with low-back pain74 (B). Both acupuncture and 
anaesthetic injection were performed at 2-5 of the most 
painful palpation points on the lower back once weekly for 
4 weeks. In the acupuncture group, 40 mm x 0.18 mm needles 
were inserted to a depth of 10-20 mm, using the bird pecking 
technique at 1 cycle per second for 20 seconds; in the local 
anaesthetic group, 5 mg of local anaesthetic were injected into 
the same points and at the same depth. Acupuncture proved 
superior to local anaesthetic for pain alleviation, with VAS 
score reductions of 49.4 ± 17.0 versus 19.5 ± 26.8 after 2 weeks 
and 51.8 ± 15.8 versus 22.1 ± 28.8 after four weeks of treatment; 
those differences were statistically significant74 (B).
Acupuncture and adverse effects
Minimal adverse effects were reported in all studies; the most 
common adverse effects were fleeting pain at the needle 
insertion site, local haematoma, mild local swelling, and 
short-term bleeding.
None of the analysed studies reported the occurrence of 
severe adverse effects.
Recommendation
Not enough studies of satisfactory quality have been found to 
enable a sound evidence-based recommendation regarding the 
use of acupuncture for the treatment of non-specific chronic 
mechanical low-back pain.
The combined use of acupuncture and conservative 
treatment modalities such as physical therapy, NSAIDs, 
analgesia, heat, self-care, and postural education was more 
beneficial than those same therapies alone for the treatment 
of non-specific chronic mechanical low-back pain65,67 (B).
There is a continued controversy regarding the efficacy 
of true acupuncture (deep needle insertion in the acupoints) 
versus that of sham acupuncture (superficial needle insertion in 
sites distant from acupoints) for the treatment of non-specific 
low-back pain. While some studies reported benefits with 
true acupuncture66,68 (A), others found both techniques to be 
equivalent67,69 (B). That controversy notwithstanding, sham 
acupuncture (superficial needle insertion) has been shown 
not to be an inert procedure. Additionally, one study found 
no benefit with the use of true acupuncture in individuals 
with chronic low-back pain compared to the use of simulated 
acupuncture72 (no actual needle insertion, but mere skin 
stimulation) (A).
Acupuncture proved more efficacious than a placebo (TENS) 
in 1 high-quality study70 (A), although this finding was not 
confirmed by another study71 (B); this discrepancy might be 
due to the differences in quality between the studies.
Acupuncture was found inferior to massage with respect to 
pain and disability after 10 weekly sessions for the treatment 
of non-specific chronic low-back pain. That difference was 
maintained at a 1-year follow-up73 (B).
Acupuncture proved to be more beneficial than local 
anaesthetic injection when both applied at the most painful 
palpation points for the treatment of chronic low-back pain74 (B).
Pain prevention
10. Is individual ergonomic orientation useful for 
preventing pain relapse?
The small number of available studies that address the 
application of ergonomics to relapse prevention in patients 
with non-specific chronic low-back pain does not yield any 
conclusive evidence in this regard75,76 (B).
A programme that included ergonomics and exercise 
for 15 1-hour sessions, conducted five days per week, was 
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not superior to individual physical therapy and spinal 
manipulation with respect to pain and disability. The results 
of the group subjected to the investigated programme, which 
included education in ergonomics at home and in different 
occupational settings, were poorer than those of the group 
subjected to spinal manipulation with respect to both pain 
and disability75 (B).
Ergonomics did not show any effect when it was used to 
prevent the relapse of low-back pain76 (B).
The ergonomic programme, which included an orientation 
about actions to reduce spinal loading, asymmetries, and 
unexpected loading related to nursing tasks, did not provide 
benefits with respect to the prevention of non-specific chronic 
low-back pain76 (B).
Recommendation
No currently available evidence allows the characterisation of 
ergonomic interventions as beneficial for the reduction and 
prevention of non-specific chronic low-back pain relapses76 (B).
11. Does the maintenance of supervised aerobic 
exercise prevent pain relapse?
Studies of individuals subjected to exercise programmes 
reported some benefits. However, neither these benefits 
nor their relevance to the overall state of health have been 
accurately investigated, as those studies included various 
confounding variables77 (A).
The small number of studies that discussed whether 
the maintenance of supervised low-intensity exercise was 
useful for preventing pain relapse and their methodological 
limitations do not yield any conclusive evidence with regard 
to either the application of that treatment modality or its 
cost-effectiveness for non-specific low-back pain78-81 (A).
Independently of its intensity and duration, exercise 
seems to be preferentially associated with the conditioning 
and wellbeing of individuals, particularly with regard to 
psychological features such as mood and self-confidence in 
the performance of the activities of daily life82-85 (A).
Nevertheless, some studies that addressed the perceptions 
of individuals at 1 and 10 years after supervised physical 
training that involved static and dynamic exercise during 
twice-weekly 1-hour sessions for at least three weeks 
suggested that these sessions contributed with improvements 
in functional capacity and to the prevention of pain relapses86 
(A)87-89 (B).
Pain reduction was observed in a study that applied a 
supervised exercise programme, divided into three phases 
of four weeks each. In the first phase (weeks 1-4), training 
therapy was performed twice weekly, with each session 
lasting for at least 1 hour and including static and dynamic 
exercises, using mainly pulleys and small weights. According 
to the individual’s physical tolerance, the weight, number of 
repetitions, speed, and range of movement were adjusted and 
gradually increased during the first phase. In the next phase 
(weeks 5-8), the sessions were performed thrice weekly for 
1 hour each, with a minimum of 2 × 15 repetitions per exercise. 
The third phase (weeks 9-12) comprised two training sessions 
per week, for 1 hour per session. Each training session started 
with a warm-up procedure that included low-impact aerobics 
and subsequent stretching86 (A).
Recommendation
No currently available evidence allows the characterisation of 
exercise as a means for preventing pain relapse. The available 
studies show that independently of the type, time, duration, 
and intensity of exercise, its benefit for the prevention of future 
episodes of pain cannot be asserted86 (A)87-89 (B).
Economic assessment
12. What is the cost-effectiveness of acupuncture 
for chronic low-back pain?
Few studies that assessed the cost-effectiveness of acupuncture 
for chronic low-back pain could be located, and in the studies 
found, assessments were performed with incremental 
cost-effectiveness analyses based on gains in the estimated 
quality-adjusted life years (QALYs).
 In the United Kingdom, for instance, a threshold 
of £ 30,000 (pounds) per QALY is found to be consistent with 
decisions to adopt new technologies. In contrast, such a 
threshold does not exist in Germany and Brazil90 (B).
One study conducted in Germany established a hypothetical 
threshold of € 50,000 (euro) per QALY. Both pain and 
quality-of-life were assessed at the baseline and at 3 and 
6 months. The sample comprised 11,630 individuals (average 
age, 52.9 years old (standard deviation, 13.7); 59% female), of 
whom 1,549 were randomised to the acupuncture group and 
1,544 to the control group, while 8,537 were included in the 
non-randomised acupuncture group. In the analysis after three 
months, back function improvements were more pronounced 
in the acupuncture group than in the control group, with mean 
HFAQ score increases of 12.1 (standard error (SE) 0.4) to 74.5 (SE, 
0.4) points in the acupuncture groups and 2.7 (SE, 0.4) to 65.1 
(SE, 0.4) points in the control group (difference, 9.4 points; 95% 
CI, 8.3-10.5; p < 0.001; control event rate = 0.631, experimental 
event rate = 0.426, RRR = 32%, ARR = 0.205, and NNT = 5). 
The non-randomised volunteers exhibited more severe 
symptoms at baseline and function improvements similar 
to those of the randomised participants. The incremental 
cost-effectiveness ratio was estimated to be € 10,526 per QALY 
gained. Acupuncture in addition to routine care was associated 
with clinical improvements in the assessed population and 
was considered relatively cost-effective91 (B).
Data analysis included the overall costs during the 3 months 
after randomisation, including costs not related to chronic 
low-back pain, as well as the diagnosis-specific costs (those 
due to chronic low-back pain and related conditions). The 
direct health-related costs included physician visits, hospital 
stays, medication, acupuncture treatment, and the number of 
sick-leave days91 (B).
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The acupuncture service was found to be cost-effective 
at 24 months; the estimated cost per QALY was £ 4,241 (95% 
CI, -£ 191 to £ 28,026), using the SF-6D scoring algorithm for 
responses to the SF-36 and £ 3,598 (95% CI, - £ 189 to £ 22,035), 
using the EQ-5D health status instrument91 (B).
The costs of acupuncture were higher than those of usual 
care, as the former involved an average of 8-10 sessions that 
lasted for 10-30 minutes per session, and 9.6 needles were used 
per treatment (range, 6-12). A total of 177 different acupoints 
were used, both unilaterally and bilaterally. The needles 
used were normally 25 or 40 mm long and 0.20-0.30 mm in 
diameter. Points from the bladder and the gallbladder channels 
were often used (38.4% and 14.9%, respectively), as was BL-23 
(22.9%); the points selected were often combinations of local 
points (e.g., BL-23, BL-26, BL-53, BL-54, and GB-30, as well as 
minor lumbar points) and distal points (e.g., BL-40, BL-60, 
GB-34, and GB-40); the addition of the costs of medical visits, 
pain medication, physical therapy, and exercise resulted in 
a total mean cost higher in the acupuncture group (£ 471.10) 
than in the control group (£ 332.24); however, the quality-of-life 
was higher in the former, while the social cost, including lost 
productivity due to time taken off from work, was lower in 
the acupuncture group (£ 2,135.39) compared to the control 
group91 (£ 2,469.09) (B).
Recommendation
Although acupuncture for the treatment of non-specific 
low-back pain is associated with a cost increase, 10 sessions at 
a twice-weekly frequency are recommended, as these improve 
the patients’ quality of life and reduce work absenteeism and 
thus reduce the individuals’ social costs91 (B).
Acupuncture in addition to routine care induced relevant 
clinical benefits and was found to be cost-effective in patients 
with chronic low-back pain who were assisted at German 
primary care centres. Therefore, acupuncture should be 
considered as a feasible option for the management of patients 
with chronic low-back pain91 (B).
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